| 000 | 05498cam a2200433Ii 4500 | ||
|---|---|---|---|
| 988 | _aSpringer_Medicine_2017 | ||
| 999 |
_c95676 _d95676 _x1 |
||
| 001 | 95676 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112716.0 | ||
| 006 | a||||fo||||\00|\0 | ||
| 007 | cr\nn\nnnaamaa | ||
| 008 | 170329s2017 sz a o 000 0 eng d | ||
| 020 |
_a3319516736 _q(electronic bk.) |
||
| 020 |
_a9783319516738 _q(electronic bk.) |
||
| 020 | _z3319516728 | ||
| 020 |
_z9783319516721 _q(print) |
||
| 040 |
_aN$T _cN$T _dEBLCP _dGW5XE _dYDX _dN$T _dOCLCQ _dNJR _dUAB _dOCLCF _dIOG _dCOO _dAZU _dUPM _dOCLCO _dMERER _dESU _dJBG _dIAD _dICN _dOCLCQ _dOCLCO _dOTZ _dVT2 _dOCLCO _dOCLCQ _dU3W _dOCLCO _dOCLCA _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRA401.A1 _b2017 EB |
|
| 245 | 0 | 0 |
_aPharmaceutical policy in countries with developing healthcare systems _cZaheer-Ud-Din Babar, editor |
| 264 | 1 |
_aCham, Switzerland _bAdis _c2017 |
|
| 300 |
_a1 recurso en línea (xii, 430 páginas) _bilustraciones (algunas a color) |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 500 | _aSpringerLink | ||
| 505 | 0 | _aForeword; Preface; Contents; Chapter 1: Introduction; 1.1 Pharmaceutical Policy and€the€Right to€Health; 1.2 Pharmaceutical Production and€Supply; 1.3 Access to€Affordable Drugs; 1.4 Conclusion; References; Part I: Low and Lower Middle Income Countries; Chapter 2: Pharmaceutical Policy in€the€East African Community: Burundi, Kenya, Uganda, Rwanda, Tanzania; 2.1 Background; 2.1.1 Focus of€This Chapter; 2.1.2 Health System of€the€EAC (Health System and€Health Indicators); 2.2 Pharmaceutical Situation of€the€EAC; 2.3 EAC Medicines Policy, Legislative and€Regulatory Environment. | |
| 505 | 8 | _a2.4 Conclusions: Summary and€Way ForwardReferences; Chapter 3: Pharmaceutical Policy in€Pakistan; 3.1 Pakistan; 3.1.1 Country Profile; 3.2 Health System of€Pakistan; 3.2.1 Health System; 3.2.2 Health Indicators; 3.3 Pharmaceutical Situation of€the€Country; 3.3.1 Pharmaceutical Industry and€Key Statistics; 3.4 Country's Regulatory Environment; 3.4.1 Medicines Regulatory Authority; 3.4.2 Quality Control; 3.4.3 Pharmacovigilance; 3.4.4 Counterfeit Medicines; 3.5 Medicines Supply System; 3.5.1 Procurement; 3.5.2 Distribution; 3.6 Medicines Financing; 3.6.1 Medicines Expenditures in€General. | |
| 505 | 8 | _a3.6.2 Medicines Pricing3.6.3 Affordability; 3.6.4 Generic Medicines; 3.7 Medicines Use (Issues Impacting on€Rationale Medicines Use in€the€Country); 3.7.1 Medicines Use in€General (in Community Pharmacies, Dispensing Doctors and€General Hospital Sector); 3.7.2 Essential Medicine List, Selection of€Essential Medicines and€Standard Treatment Guidelines; 3.7.3 Prescribing Behaviour in€General (Factors Affecting Prescribing Behaviour); 3.7.4 Medicines' Promotional Practices; 3.7.5 The Role of€Pharmacist in€Community and€Hospital Environments. | |
| 505 | 8 | _a3.7.6 Medicines Use Research (Including Drug Utilization Evaluation Research)3.8 Summary and€Future Direction; References; Chapter 4: Pharmaceutical Policy in€the€Philippines; 4.1 The Philippines Health System; 4.1.1 Health System of€Philippines; 4.1.2 Health Indicators; 4.2 The Philippines Pharmaceutical Sector; 4.3 Pharmaceutical Regulation in€the€Philippines; 4.3.1 Quality Control; 4.3.2 Pharmacovigilance; 4.3.3 Substandard and€Counterfeit Medicines; 4.4 Medicines Supply System in€the€Philippines; 4.4.1 The Medicines Supply System; 4.5 Medicines Financing; 4.5.1 Medicine Pricing. | |
| 505 | 8 | _a4.5.2 Price Monitoring4.5.3 Medicines Access; 4.5.4 Medicines Access Programs of€the€DOH; 4.5.5 Industry Patient Assistance Programmes; 4.5.6 Generic Medicines; 4.6 Medicines Use; 4.6.1 Medicines Use in€General; 4.6.2 Essential Medicines and€Standard Treatment Guidelines; 4.6.3 Pharmacoeconomics; 4.6.4 Prescribing Behaviour; 4.6.5 Medicines Promotional Practices; 4.6.6 Role of€Pharmacist; 4.6.7 Pharmaceutical Care Interventions and€Assessment of€Community Pharmacy Practice; 4.6.8 Medicines Use Research; 4.7 Conclusions and€Way Forward; References; Chapter 5: Pharmaceutical Policy in€Vietnam. | |
| 520 | 3 | _aA comprehensive and granular insight into the challenges of promoting rational medicine, this book serves as an essential resource for health policy makers and researchers interested in national medicines policies. Country-specific chapters have a common format, beginning with an overview of the health system and regulatory and policy environments, before discussing the difficulties in maintaining a medicines supply system, challenges in ensuring access to affordable medicines and issues impacting on rational medicine use. Numerous case studies are also used to highlight key issues and each chapter concludes with country-specific solutions to the issues raised. Written by highly regarded academics, the book includes countries in Africa, Asia, Europe, the Middle East and South America. | |
| 588 | 0 | _aOnline resource; title from PDF title page (SpringerLink, viewed April 12, 2017). | |
| 650 | 7 |
_aPolítica sanitaria _2embne _9405188 |
|
| 700 | 1 |
_aBabar, Zaheer-ud-din, _eeditor literario _995144 |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-51673-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b09/2020 _dz _ea _zSI |
||